Education
About Us
Working with TipRanks
Follow Us
Legend Biotech Corporation (LEGN)
NASDAQ:LEGN
LEGN Stock Chart & Stats
$32.12
-$0.50(-1.49%)
At close: 4:00 PM EST
$32.12
-$0.50(-1.49%)
Day’s Range― - ―
52-Week Range$27.34 - $47.79
Previous CloseN/A
Volume249.07K
Average Volume (3M)1.33M
Market Cap
$5.88B
Enterprise Value$5.96B
Total Cash (Recent Filing)$967.64M
Total Debt (Recent Filing)$387.92M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Nov 24, 2025EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding184,570,710
10 Day Avg. Volume1,557,434
30 Day Avg. Volume1,328,447
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)2.86
Price to Sales (P/S)4.74
P/FCF Ratio-18.81
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue7.47
Enterprise Value/Gross Profit12.08
Enterprise Value/Ebitda-22.87
Forecast
1Y Price Target
$72.44Price Target Upside125.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Bulls Say, Bears Say
Bulls Say
EarningsLegend reported another record quarter with CARVYKTI 2Q25 sales of $439M which exceeded expectations, setting their product as the highest selling CAR-T therapy.
Manufacturing CapacityManagement has reiterated guidance of manufacturing 10,000 doses by year-end with an expansion to its Raritan facility and initiation of commercial production at Tech Lane Belgium Facility coming online in the second half of 2025.
Market ExpansionThe diverse pipeline and continuous expansion of Carvykti through approvals in earlier lines and regions support the analyst's Outperform rating.
Bears Say
Competitive PressureBispecific growth validates demand but might temper 2L CAR-T use, potentially creating competitive headwinds for CARVYKTI.
Legend Biotech News
LEGN FAQ
What was Legend Biotech Corporation’s price range in the past 12 months?
Legend Biotech Corporation lowest stock price was $27.34 and its highest was $47.79 in the past 12 months.
What is Legend Biotech Corporation’s market cap?
Legend Biotech Corporation’s market cap is $5.88B.
When is Legend Biotech Corporation’s upcoming earnings report date?
Legend Biotech Corporation’s upcoming earnings report date is Nov 24, 2025 which is in 26 days.
How were Legend Biotech Corporation’s earnings last quarter?
Legend Biotech Corporation released its earnings results on Aug 11, 2025. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.113 by -$0.227.
Is Legend Biotech Corporation overvalued?
According to Wall Street analysts Legend Biotech Corporation’s price is currently Undervalued.
Does Legend Biotech Corporation pay dividends?
Legend Biotech Corporation does not currently pay dividends.
What is Legend Biotech Corporation’s EPS estimate?
Legend Biotech Corporation’s EPS estimate is -0.07.
How many shares outstanding does Legend Biotech Corporation have?
Legend Biotech Corporation has 184,570,710 shares outstanding.
What happened to Legend Biotech Corporation’s price movement after its last earnings report?
Legend Biotech Corporation reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.113. Following the earnings report the stock price went down -2.054%.
Which hedge fund is a major shareholder of Legend Biotech Corporation?
Currently, no hedge funds are holding shares in LEGN
Legend Biotech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$72.44 (125.53% Upside)
$72.44 (125.53% Upside)
Blogger Sentiment
Bullish
LEGN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 14.1%
Last 30 Days ▲ 14.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.20%
12-Months-Change
Fundamentals
Return on Equity
-29.71%
Trailing 12-Months
Asset Growth
-6.02%
Trailing 12-Months
Company Description
Legend Biotech Corporation
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
LEGN Company Deck
LEGN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a predominantly positive sentiment with significant achievements in sales growth, regulatory advancements, and clinical trial results. The company's strategic expansion in global markets and operational improvements further bolster this positive outlook. However, challenges such as ongoing net losses and early-stage community oncology expansion temper the overall sentiment.View all LEGN earnings summariesLEGN Stock 12 Month Forecast
Average Price Target
$72.44
▲(125.53% Upside)
Technical Analysis
Cytokinetics
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Avidity Biosciences
―
Abivax SA Sponsored ADR
―
Ownership Overview
―
Insiders
15.26% Mutual Funds
0.04% Other Institutional Investors
82.06% Public Companies and
Individual Investors